AP NEWS

Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS, and AMAG Pharmaceuticals — What Drives Growth in Today’s Competitive Landscape

November 8, 2018

NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KB Home (NYSE:KBH), Lennox International, Inc. (NYSE:LII), CorVel Corp. (NASDAQ:CRVL), Acorda Therapeutics, Inc. (NASDAQ:ACOR), PROS Holdings, Inc. (NYSE:PRO), and AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

KBH DOWNLOAD: http://Fundamental-Markets.com/register/?so=KBH LII DOWNLOAD: http://Fundamental-Markets.com/register/?so=LII CRVL DOWNLOAD: http://Fundamental-Markets.com/register/?so=CRVL ACOR DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACOR PRO DOWNLOAD: http://Fundamental-Markets.com/register/?so=PRO AMAG DOWNLOAD: http://Fundamental-Markets.com/register/?so=AMAG

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine KB Home (NYSE:KBH), Lennox International, Inc. (NYSE:LII), CorVel Corp. (NASDAQ:CRVL), Acorda Therapeutics, Inc. (NASDAQ:ACOR), PROS Holdings, Inc. (NYSE:PRO), and AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 6th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

KB HOME (KBH) REPORT OVERVIEW

KB Home’s Recent Financial Performance

For the three months ended August 31st, 2018 vs August 31st, 2017, KB Home reported revenue of $1,225.35MM vs $1,144.00MM (up 7.11%) and analysts estimated basic earnings per share $0.99 vs $0.58 (up 70.69%). For the twelve months ended November 30th, 2017 vs November 30th, 2016, KB Home reported revenue of $4,368.53MM vs $3,594.65MM (up 21.53%) and analysts estimated basic earnings per share $2.09 vs $1.23 (up 69.92%). Analysts expect earnings to be released on January 9th, 2019. The report will be for the fiscal period ending November 30th, 2018. The reported EPS for the same quarter last year was $0.84. The estimated EPS forecast for the next fiscal year is $3.20 and is expected to report on January 9th, 2019.

To read the full KB Home (KBH) report, download it here: http://Fundamental-Markets.com/register/?so=KBH

-----------------------------------------

LENNOX INTERNATIONAL, INC. (LII) REPORT OVERVIEW

Lennox International’s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Lennox International reported revenue of $1,030.20MM vs $1,052.30MM (down 2.10%) and analysts estimated basic earnings per share $2.68 vs $2.47 (up 8.50%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Lennox International reported revenue of $3,839.60MM vs $3,641.60MM (up 5.44%) and analysts estimated basic earnings per share $7.25 vs $6.39 (up 13.46%). Analysts expect earnings to be released on February 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $1.68. The estimated EPS forecast for the next fiscal year is $11.69 and is expected to report on February 5th, 2019.

To read the full Lennox International, Inc. (LII) report, download it here: http://Fundamental-Markets.com/register/?so=LII

-----------------------------------------

CORVEL CORP. (CRVL) REPORT OVERVIEW

CorVel’s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, CorVel reported revenue of $148.18MM vs $136.43MM (up 8.61%) and analysts estimated basic earnings per share $0.68 vs $0.45 (up 51.11%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, CorVel reported revenue of $558.35MM vs $518.69MM (up 7.65%) and analysts estimated basic earnings per share $1.90 vs $1.52 (up 25.00%). Analysts expect earnings to be released on January 29th, 2019. The report will be for the fiscal period ending December 31st, 2018.

To read the full CorVel Corp. (CRVL) report, download it here: http://Fundamental-Markets.com/register/?so=CRVL

-----------------------------------------

ACORDA THERAPEUTICS, INC. (ACOR) REPORT OVERVIEW

Acorda Therapeutics’ Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Acorda Therapeutics reported revenue of $153.30MM vs $139.44MM (up 9.94%) and basic earnings per share $0.99 vs -$0.18. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Acorda Therapeutics reported revenue of $588.29MM vs $519.60MM (up 13.22%) and analysts estimated basic earnings per share -$4.86 vs -$0.76. Analysts expect earnings to be released on February 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.45. The estimated EPS forecast for the next fiscal year is -$4.11 and is expected to report on February 21st, 2019.

To read the full Acorda Therapeutics, Inc. (ACOR) report, download it here: http://Fundamental-Markets.com/register/?so=ACOR

-----------------------------------------

PROS HOLDINGS, INC. (PRO) REPORT OVERVIEW

PROS’s Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, PROS reported revenue of $49.08MM vs $41.94MM (up 17.02%) and analysts estimated basic earnings per share -$0.44 vs -$0.67. For the twelve months ended December 31st, 2017 vs December 31st, 2016, PROS reported revenue of $168.82MM vs $153.28MM (up 10.14%) and analysts estimated basic earnings per share -$2.46 vs -$2.47. Analysts expect earnings to be released on February 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.29. The estimated EPS forecast for the next fiscal year is -$0.99 and is expected to report on February 5th, 2019.

To read the full PROS Holdings, Inc. (PRO) report, download it here: http://Fundamental-Markets.com/register/?so=PRO

-----------------------------------------

AMAG PHARMACEUTICALS, INC. (AMAG) REPORT OVERVIEW

AMAG Pharmaceuticals’ Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, AMAG Pharmaceuticals reported revenue of $122.24MM vs $124.33MM (down 1.68%) and analysts estimated basic earnings per share $0.89 vs -$4.31. For the twelve months ended December 31st, 2017 vs December 31st, 2016, AMAG Pharmaceuticals reported revenue of $609.95MM vs $532.09MM (up 14.63%) and analysts estimated basic earnings per share -$5.71 vs -$0.07. Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.10. The estimated EPS forecast for the next fiscal year is -$2.81 and is expected to report on February 26th, 2019.

To read the full AMAG Pharmaceuticals, Inc. (AMAG) report, download it here: http://Fundamental-Markets.com/register/?so=AMAG

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers (“Registered Members”) working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

AP RADIO
Update hourly